Loading patent…
OwnerMarsha A. Moses, Susan Pories +1inventors
InventorsMarsha A. Moses, Susan Pories, David Zurakowski
Estimating the term…
We show that urinary metalloproteinases (MMP's) (e.g. MMP 9) and a disintegrin and metalloprotease 12 (ADAM 12) are significantly elevated in women at high risk for developing breast cancer and that monitoring for the absence or presence of both MMP 9 and ADAM 12 represents a new means for breast cancer risk assessment. In addition, we show that levels of MMP 9 and ADAM 12 serve as independent predictors of breast cancer risk. Furthermore, we have determined that elevated levels of urinary ADAM 12 predict an increased risk for breast cancer in subjects predicted not to be at risk for breast cancer by the Gail 5 -year risk model66,67. Accordingly, methods for assessing breast cancer risk and methods for directing medical care are provided.
A method for assessing breast cancer risk in a subject comprising:
A method for assessing breast cancer risk in a subject comprising:
4-9. (canceled)
(canceled)
13-17. (canceled)
A method for monitoring therapeutic efficacy of a breast cancer risk reduction strategy, wherein the status of ADAM 12 presence and the status of MMP 9 presence in a biological sample from a subject is used for the assessment of breast cancer risk in the subject, wherein reduction in the levels of ADAM 12 and/or the reduction in the levels of MMP 9 indicates that the breast cancer risk reduction strategy is efficacious.
A method for monitoring therapeutic efficacy in a subject of a breast cancer risk reduction strategy comprising the steps of:
A method for assessing breast cancer risk in a subject that is at low risk for breast cancer according to the Gail 5-year risk model comprising:
(canceled)
24-34. (canceled)
A method for monitoring therapeutic efficacy of a breast cancer risk reduction strategy, wherein the level of ADAM 12 in a biological sample from a subject that is at low risk for breast cancer according to the Gail 5-year risk model is used for the assessment of breast cancer risk in the subject, wherein reduction in the levels of ADAM 12 indicates that the breast cancer risk reduction strategy is efficacious.
A method to direct treatment of a subject which comprises having a subject tested for the presence of ADAM 12 and the presence of MMP 9 in a biological sample obtained from the subject, wherein a clinician reviews the results and if the biological sample is positive for the presence of ADAM 12 and the presence of MMP 9 the clinician directs the subject to appropriate medical treatment.
A method to direct treatment of a subject which comprises having a subject tested for the level of ADAM 12 in a biological sample a biological sample from a subject that is at low risk for breast cancer according to the Gail 5-year risk model, wherein a clinician reviews the results as compared to a standard level of ADAM 12, and if the biological sample has an elevated level of ADAM 12 as compared to the standard level the clinician directs the subject to appropriate medical treatment.
39-41. (canceled)
A method for assessing breast cancer risk in a subject comprising:
A method for assessing breast cancer risk in a subject comprising:
(canceled)
Dependencies are inferred from the claim text.